KPC's 2024 net profit attributable to shareholders up 19.86%

China Resources Pharmaceutical Group Limited (HKEX:3320) announced the principal financial information of its subsidiary KPC Pharmaceuticals, Inc. for the year ended December 31, 2024. KPC's annual report, released March 11, 2025, revealed a 19.86% increase in net profit attributable to shareholders of the listed company, reaching RMB 648,081,341.92 compared to RMB 540,710,565.96 in 2023. Total assets increased by 2.57% to RMB 12,611,367,133.57. The basic and diluted earnings per share both rose to RMB 0.86, a 21.13% increase year-over-year. Revenue saw a slight decrease of -0.34% to RMB 8,401,447,233.37. KPC has proposed a cash dividend of RMB 3.00 per 10 shares, pending shareholder approval. The company advises caution to investors dealing in securities, urging them not to rely solely on this information.